Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
2005

Reducing Breast Cancer Risk with Prophylactic Surgery

Sample size: 148 publication 10 minutes Evidence: moderate

Author Information

Author(s): van Sprundel T C, Schmidt M K, Rookus M A, Brohet R, van Asperen C J, Rutgers E J Th, van‘t Veer L J, Tollenaar R A E M

Primary Institution: Leiden University Medical Center

Hypothesis

Does contralateral prophylactic mastectomy (CPM) reduce the risk of contralateral breast cancer and improve survival in BRCA1 or BRCA2 mutation carriers?

Conclusion

CPM significantly reduces the risk of contralateral breast cancer among BRCA1 or BRCA2 mutation carriers, but its effect on overall survival is not significant after adjusting for other factors.

Supporting Evidence

  • CPM reduced the risk of contralateral breast cancer by 91%.
  • Overall survival was 94% for the CPM group compared to 77% for the surveillance group.
  • After adjusting for other factors, the survival benefit of CPM was no longer significant.

Takeaway

Women with certain gene mutations can lower their chances of getting breast cancer in the other breast by having surgery to remove it, but this doesn't always help them live longer.

Methodology

The study included 148 women with BRCA1 or BRCA2 mutations and a history of unilateral invasive breast cancer, comparing outcomes between those who underwent CPM and those who were under surveillance.

Potential Biases

Potential bias due to the retrospective nature of the study and differences in treatment choices between groups.

Limitations

The study is retrospective and may be subject to bias, including testing and survival bias.

Participant Demographics

All participants were female BRCA1 or BRCA2 mutation carriers with a history of unilateral invasive breast cancer.

Statistical Information

P-Value

P<0.001 for contralateral breast cancer risk; P=0.03 for overall survival comparison.

Confidence Interval

95% CI 0.01–0.78 for contralateral breast cancer risk; 95% CI 0.07–1.39 for overall mortality.

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6602703

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication